Fred Bunz, MD, PhD

Phone number: (410) 502-7941

Interests: Cancer genetics

Title: Associate Professor

Schools\degrees: Stony Brook University\MD, PhD

Training: Johns Hopkins Medicine and Howard Hughes Medical Institution\Postdoctoral fellowships

Research summary: My research objective is to understand the genetic basis of common cancers, and to determine how recurrent genetic alterations affect treatment with existing and novel therapeutic agents.

Journal citations (since 2006)

Matoba S, Kang J-G, Patino WD, Wragg A, Boehm M, Gavrilova O, Hurley PJ, Bunz F, Hwang PM. p53 Regulates Mitochondrial Respiration. Science. 2006; 312:1650-1653.

Hurley PJ, Wilsker D, Bunz F. Human cancer cells require ATR for cell cycle progression following exposure to ionizing radiation. Oncogene. 2007; 26:2535-42.

Gallmeier E, Hucl T, Calhoun ES, Cunningham, Bunz F, Brody JR, Kern SE. Gene-specific selection against acute Fanconi Anemia gene inactivation in human cancer cells. Cancer Biol Ther. 2007 6:1406-13.

Hurley PJ and Bunz F. ATM and ATR: components of an integrated circuit. Cell Cycle. 2007; 6:1406-1413.

Wilsker D and Bunz F. Loss of ATR function potentiates the effects of chemotherapeutic drugs on cancer cell survival. Mol Cancer Ther. 2007; 6:1406-1413.

Rago C, Vogelstein B, Bunz F. Genetic knockouts and knockins in human somatic cells. Nat Protoc. 2007; 2:2734-2746.

Horowitz DP, Topaloglu O, Zhang Y, Bunz F. Deficiency of Bloom syndrome helicase activity is radiomimetic. Cancer Biol Ther. 2008; 7:1778-1781.

Kim J-S, Bonifant C, Bunz F, Lane W, Waldman T. Epitope tagging of endogenous genes in diverse human cell lines. Nucleic Acids Res. 2008; 36:e127.

Singh A, Boldin-Adamsky S, Thimmulappa RK, Rath SK, Ashush H, Coulter J, Blackford A, Goodman SN, Bunz F, Watson WH, Gabrielson E, Feinstein E, Biswal S. RNAi-mediated silencing of nuclear factor erythroid-2-related factor 2 gene expression in non-small cell lung cancer inhibits tumor growth and increases efficacy of chemotherapy. Cancer Res. 2008; 68:7975-7984.

Wilsker D, Petermann E, Helleday T, Bunz F. Essential function of Chk1 can be uncoupled from DNA damage checkpoint and replication control. Proc Natl Acad Sci USA. 2008; 105:20752-20757.

Sur S, Pagliarini R, Bunz F, Rago C, Diaz LA Jr, Kinzler KW, Vogelstein B, Papadopoulos N. A panel of isogenic human cancer cells suggests a therapeutic approach for cancers with inactivated p53. Proc Natl Acad Sci USA. 2009; 106:3964-3969.

Chung JH, Bunz F. Cdk2 is required for p53-independent G₂/M checkpoint control. PLoS Genetics. 2010 6:e1000863.

Sung HJ, Ma W, Wang P-Y, Hynes J, O’Riordan TC, Combs CA, McCoy JP, Bunz F, Kang J-G, Hwang PM. Mitochondrial respiration protects against oxygen-associated DNA damage. Nat Comm. 2010; 1:1-18.

Singh A, Bodas M, Wakabayashi N, Bunz F, Biswal S. Gain of Nrf2 function in non-small cell lung cancer cells confers radioresistance. Antioxid Redox Signal. 2010; 13:1627-1637.

Chung JH, Zhang, Y, Bunz F. Checkpoint bypass and cell viability. Cell Cycle. 2010; 9:1-6.

Sangster-Guity N, Conrad BH, Papadopoulos N, Bunz F. ATR mediates cisplatin resistance in a p53 genotype-specific manner. Oncogene. 2011; In Press.

Gallmeier E, Hermann PC, Mueller MT, Machado JG, Ziesch A, De Toni EN, Palagyi A, Eisen C, Ellwart JW, Rivera J, Rubio-Viqueira B, Hidalgo M, Bunz F, Goke B, Heeschen C. Inhibition of ATR function abrogates the in vitro and in vivo tumorigenicity of human colon cancer cells through depletion of the CD133+ tumor-initiating cell fraction. Stem Cells. 2011; 29:418-429.